Patent ID: 8481503

Claim:
A combined anticancer agent for simultaneous, separate or successive administration in cancer therapy, comprising the following pharmaceutical preparations (a) and (b): (a) a pharmaceutical preparation comprising 8-[4-(1-aminocyclobutyl)phenyl]-9phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, and (b) a pharmaceutical preparation comprising, together with a pharmaceutically acceptable carrier or diluent, at least one anticancer agent selected from the group consisting of anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors, or a pharmaceutically acceptable salt thereof, wherein the anticancer antimetabolites are 5-fluorouracil and gemcitabine; the anticancer antibiotics is doxorubicin; the plant-derived anticancer agents are docetaxel and paclitaxel; the anticancer platinum-coordinated complex compounds are cisplatin and carboplatin; the anticancer camptothecin derivatives is camptothecin; and the anticancer tyrosine kinase inhibitors are lapatinib and erlotinib and wherein the cancer is selected from breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer and prostate cancer.